AusperBio to Present Long-Term AHB-137 Data at AASLD The Liver Meeting® 2026

SAN FRANCISCO, Oct. 7, 2026 /CourierPR/ -- AusperBio Therapeutics, Inc., a near-commercial biopharmaceutical company, is set to present long-term follow-up data of AHB-137 treatment for chronic hepatitis B at The Liver Meeting® 2026. The presentations, selected as late-breaking oral presentations, will provide insights into the efficacy and durability of AHB-137 treatment in two distinct patient populations.

This session is scheduled for November 8, 2026, at 2:00 pm, 2:15 pm Mountain Time (MT).

This session is set for November 8, 2026, at 6:00 pm, 6:15 pm MT.

The presentations will be available on the AASLD website starting at 8:00 am MT on November 5, 2026. AusperBio plans to issue a press release with additional details following the presentations.

AHB-137 is AusperBio's lead investigational unconjugated antisense oligonucleotide (ASO) therapy for chronic hepatitis B. Developed using the Company's proprietary Med-Oligo™ ASO platform, AHB-137 is designed to suppress hepatitis B surface antigen (HBsAg) production, inhibit viral DNA replication, and promote immune reactivation. The goal is to achieve a functional cure for chronic hepatitis B. AHB-137 has demonstrated promising clinical results and is currently being evaluated in a Phase 3 trial in China, following completion of a global Phase 1 study and multiple Phase 2 studies.

AusperBio is a near-commercial biopharmaceutical company focused on developing differentiated oligonucleotide therapeutics and targeted delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B. The Company's innovation engine is built on its proprietary Med-Oligo™ ASO and Au-HALO™ targeted delivery platforms, supporting the development of therapies across multiple oligonucleotide modalities. With multiple clinical-stage programs and a growing pipeline, AusperBio is advancing a backbone-based combination strategy for functional cure of CHB while exploring opportunities in additional disease areas with significant unmet medical needs.

The presentations will cover long-term follow-up data from the AB-10-8004 study (NCT07146100), which includes participants who were either nucleos(t)ide analogue (NA) treatment-experienced or treatment-naive and received AHB-137 monotherapy. The data will provide critical insights into the long-term efficacy and safety of AHB-137 in these patient populations.

The AB-10-8004 study, which is a key part of AusperBio's ongoing research, aims to evaluate the durability of AHB-137 treatment in participants who have completed prior clinical studies. The study's findings will be crucial for understanding the long-term impact of AHB-137 on chronic hepatitis B, a condition that affects millions of people worldwide and remains a significant public health challenge.

The presentations will be of great interest to the hepatology community, as they will provide valuable data that could inform future treatment strategies and clinical guidelines for chronic hepatitis B. The results from these late-breaking oral presentations could potentially accelerate the development of AHB-137 and bring us closer to a functional cure for this debilitating disease.